NVS Jan 2024 80.000 call
| Previous close | 11.50 |
| Open | 11.50 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 80.00 |
| Expiry date | 2024-01-19 |
| Day's range | 11.50 - 11.50 |
| Contract range | N/A |
| Volume | |
| Open interest | 75 |
- Zacks
Novartis (NVS) NSCLC Study Fails to Meet Primary Endpoint
Novartis (NVS) suffers a setback as canakinumab fails to meet the primary goal in yet another study for lung cancer.
- Zacks
Bausch (BHC) to Appeal Regarding Xifaxan Patent Decision
Bausch (BHC) will appeal to the U.S. Court of Appeals for the Federal Circuit regarding the patent decision for one of its key drugs Xifaxan.
- GlobeNewswire
Novartis provides update on Phase III CANOPY-A study evaluating canakinumab as adjuvant treatment in non-small cell lung cancer
Phase III CANOPY-A trial did not meet primary endpoint of disease-free survival in patients with stages II-IIIA and IIIB completely resected non-small cell lung cancer1Findings will be presented at an upcoming medical meetingNovartis remains committed to pursuing new therapeutic options that can have a meaningful impact on the lives of people with lung cancer Basel, August 15, 2022 — Novartis announced today that the Phase III CANOPY-A study evaluating adjuvant treatment with canakinumab (ACZ885
